**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 74557

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Cohort Study***

**Contemporary, national patterns of surgery after preoperative therapy for stage II/III rectal adenocarcinoma**

Soriano C *et al*. Rectal cancer surgery after preoperative therapy

Celine Soriano, Henry T Bahnson, Jennifer A Kaplan, Bruce Lin, Ravi Moonka, Huong T Pham, Hagen F Kennecke, Vlad Simianu

**Celine Soriano, Jennifer A Kaplan, Ravi Moonka,** Department of Surgery, Virginia Mason Franciscan Health, Seattle, WA 98101, United States

**Henry T Bahnson,** Benaroya Research Institute, Seattle, WA 98101, United States

**Bruce Lin,** Department of Hematology Oncology, Virginia Mason Franciscan Health, Seattle, WA 98101, United States

**Huong T Pham,** Department of Radiation Oncology, Virginia Mason Franciscan Health, Seattle, WA 98101, United States

**Hagen F Kennecke,** Department of Medical Oncology, Providence Cancer Instititute, Portland, OR 97213, United States

**Vlad Simianu,** Section of Colon and Rectal Surgery, Department of Surgery, Virginia Mason Medical Center, Seattle, WA 98101, United States

**Author contributions:** All authors have made substantial contributions to conception and design of the study, acquisition of data, or analysis and interpretation of data, been actively involved in drafting the article or making critical revisions related to important intellectual content of the manuscript, and have provided final approval of the version of the article to be published.

**Corresponding author: Vlad Simianu, FACS, MD, Director, Surgeon,** Section of Colon and Rectal Surgery, Department of Surgery, Virginia Mason Medical Center, 1100 Ninth Ave C6-GS, Seattle, WA 98101, United States. vlad.simianu@commonspirit.org

**Received:** December 29, 2021

**Revised:** April 11, 2022

**Accepted:** May 22, 2022

**Published online:** June 15, 2022

**Abstract**

BACKGROUND

Contemporary treatment of stage II/III rectal cancer combines chemotherapy, chemoradiation, and surgery, though the sequence of surgery with neoadjuvant treatments and benefits of minimally-invasive surgery (MIS) is debated.

AIM

To describe patterns of surgical approach for stage II/III rectal cancer in relation to neoadjuvant therapies.

METHODS

A retrospective cohort was created using the National Cancer Database. Primary outcome was rate of sphincter-sparing surgery after neoadjuvant therapy. Secondary outcomes were surgical approach (open, laparoscopic, or robotic), surgical quality (R0 resection and 12+ lymph nodes), and overall survival.

RESULTS

A total of 38927 patients with clinical stage II or III rectal adenocarcinoma underwent surgical resection from 2010-2016. Clinical stage II patients had neoadjuvant chemoradiation less frequently compared to stage III (75.8% *vs* 84.7%, *P* < 0.001), but had similar rates of total neoadjuvant therapy (TNT) (27.0% *vs* 27.2%, *P* = 0.697). Overall rates of total mesorectal excision without sphincter preservation were similar between clinical stage II and III (30.0% *vs* 30.3%) and similar if preoperative treatment was chemoradiation (31.3%) or TNT (30.2%). Over the study period, proportion of cases approached laparoscopically increased from 24.9% to 32.5% and robotically 5.6% to 30.7% (*P* < 0.001). This cohort showed improved survival for MIS approaches compared to open surgery (laparoscopy HR 0.85, 95%CI 0.78-0.93, and robotic HR 0.82, 95%CI 0.73-0.92).

CONCLUSION

Sphincter preservation rates are similar across stage II and III rectal cancer, regardless of delivery of preoperative chemotherapy, chemoradiation, or both. At a national level, there is a shift to predominantly MIS approaches for rectal cancer, regardless of whether sphincter sparing procedure is performed.

**Key Words:** Rectal cancer; Total neoadjuvant therapy; Colorectal surgery; Minimally-invasive surgery; Chemotherapy; Radiation

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Soriano C, Bahnson HT, Kaplan JA, Lin B, Moonka R, Pham HT, Kennecke HF, Simianu V. Contemporary, national patterns of surgery after preoperative therapy for stage II/III rectal adenocarcinoma. *World J Gastrointest Oncol* 2022; 14(6): 1148-1161

**URL:** https://www.wjgnet.com/1948-5204/full/v14/i6/1148.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v14.i6.1148

**Core Tip:** At a population level, there have been increases in neoadjuvant treatment and minimally-invasive surgical (MIS) approaches for stage II and III rectal cancer. These shifts have are not associated with changes in rates of permanent ostomy which remain about 30%. In contrast to prior trials, this ‘real-world’ cohort showed an association with higher quality surgical resection and improved survival with MIS.

**INTRODUCTION**

The management of rectal cancer has evolved, with emphasis on optimizing oncological outcomes and minimizing operative morbidity. Treatment of locally advanced rectal cancer typically involves multimodality therapies and total mesorectal excision (TME)[1,2]. Neoadjuvant therapy using chemotherapy and/or radiotherapy has several advantages, such as locoregional control and improved overall survival, compared to surgery alone[3–5]. Additionally, the administration of chemoradiation combined with induction or consolidation chemotherapy, known as total neoadjuvant therapy (TNT), has gained popularity due to increased treatment compliance without compromise of pathologic complete response or complete resection rates[6–8].

Despite advances in multimodality treatment paradigms, the optimal sequence of surgery in relation to chemotherapy and radiation remains unknown. Recent trials have assessed pre-operative treatment regimens and improved rates of organ preservation, disease free survival, and pathological complete response rates in patients with high risk, locally advanced rectal cancer[9-11]. Several factors, including anatomic considerations, tumor features, and functional symptoms, can influence decision-making, and treatment is typically individualized. Due to the complexity of rectal cancer care, variation has been described, with differences in curative resection rates, postoperative morbidity and mortality, and long-term oncologic outcomes among both surgeons and hospitals[12]. Furthermore, practices of how surgery is sequenced with other modalities, especially in the era of minimally invasive surgery (MIS), is not well described.

Therefore, the aim of this study was to characterize surgical resection of locally advanced rectal adenocarcinoma in the setting of multimodal therapy at the national level, with a focus on describing patterns of surgery in sequence with neoadjuvant treatment delivery and shift in surgical approach trends over time. We hypothesized that there would be increases in the delivery of neoadjuvant chemotherapy and chemoradiation, performance of sphincter-sparing resections, and use of minimally invasive surgical approaches.

**MATERIALS AND METHODS**

This study was determined to be exempt from human subjects review by the Benaroya Research Institute Institutional Review Board.

***Data/population***

A retrospective cohort of patients with clinical stage II and stage III rectal adenocarcinoma who underwent surgical resection between 2010 and 2016 was created using the National Cancer Database (NCDB). The NCDB is a validated national cancer registry of the American College of Surgeons and American Cancer Society, collected from more than 1500 Commission on Cancer-accredited facilities. Stage was defined according to the seventh edition of the American Joint Committee on Cancer’s clinical group. The cohort was based on clinical stage, rather than pathologic stage, as treatment delivery is established once staging workup is complete. Patients with a diagnosis of multiple cancers and undergoing palliative surgery were excluded (Figure 1).

***Outcomes/definitions***

To describe patterns of surgical care delivery, the primary outcome was proportion of patients receiving local excision or TME with or without sphincter preservation. The frequency of sphincter preservation was characterized by surgery alone or in sequence with chemotherapy or radiation therapy. Using NCDB definitions, local excision was defined as conventional trans-anal excision or trans-anal endoscopic microsurgery. TME with sphincter preservation was defined as any rectal resection that included anastomosis [low anterior resection (LAR) and total proctocolectomy and pouch-anal anastomosis]. TME without sphincter preservation was defined as any rectal resection without anastomosis [abdominoperineal resection (APR), LAR with colostomy, and total proctocolectomy with ileostomy]. Surgical approach to TME was subcategorized into open, laparoscopic, and robotic. Conversion to open from laparoscopy and robotics was also reported, but these cases were included in their intended approach categories. Chemotherapy delivery was defined as single or multi-agent systemic administration before or after surgery. TNT was defined as delivery of both multiagent chemotherapy and radiation therapy prior to surgical date.

Secondary outcomes that were assessed include pathologic stage, quality of surgical resection, and overall survival. Quality of surgical resection included proportion of cases with negative margins, total lymph node harvest and proportion of cases with 12+ lymph nodes harvested. To explore potential variation in care delivery, patient factors (age, sex, insurance status, comorbidities) and location of care (facility information, geographic area) were described and used as covariates in the survival analysis. Comorbidities were defined using the Charlson-Deyo comorbidity index.

***Statistical analysis***

Categorical and continuous variables based on clinical interest were compared with chi-square and Kruskal Wallis tests, respectively. While the hypothesis did not focus on differences in treatment based on rectal cancer stage, stage-specific data are provided in supplemental text (Supplementary Table 1). Because of the expected uptake of MIS over time, we described trends in surgical approach by year. Test for trend of surgical approach were done with Chi-squared test. Univariate- and multivariate-adjusted overall survival analyses were performed using cox proportional hazards model on a subset of the analysis sample, excluding patients with multiple cancers or where treatment and diagnosis were done at different facilities, as per NCDB recommendations. The final survival model was adjusted for age, sex, race, insurance, rurality, geography, facility type, pathologic stage, cancer grade, preoperative radiation, chemotherapy type and sequence, surgery type (LE, TME with or without sphincter preservation), intent of surgical approach (open, laparoscopic, robotic), resection margin status and 12+ lymph nodes resected status. Kaplan Meier survival curves stratified by TME with and without sphincter preservation are shown, by intent of surgical approach (open, laparoscopic, robotic). Statistical significance was determined by *P* < 0.05. Survival and patient characteristics tables were run with Mayo Clinic’s SAS macros[13] on SAS version 9.4 and JMP Pro Version 15 was also used for graphics and data analysis.

**RESULTS**

***Patient demographics and sequence of treatment***

From 2010-2016, a total of 38,927 patients underwent resection of stage II/III rectal cancer (mean age 60.9 ± 12.7 years, and 61% male). Baseline patient and facility characteristics are outlined in Table 1. Sphincter was not preserved in 30.2% (*n* = 11748). Patients with clinical stage III disease represented 55% of the cohort, and stage distribution was similar whether TME with sphincter preservation (55.5%) or not (54.9%) was performed. It was rare to undergo local excision after initially presenting with clinical stage II (5.2%) or clinical stage III (2.5%) rectal cancer.

***Sequence of treatment by stage***

Patients with clinical stage II disease more frequently had no radiation (16.8% *vs* 8.7%, *P* < 0.001) or no chemotherapy (14.9% *vs* 5.9%, *P* < 0.001) compared to clinical stage III patients (Supplementary Table 1). Clinical stage II patients less frequently had neoadjuvant chemoradiation (75.2%, *vs* 84.1% *P* < 0.001), but had similar rates of TNT (27.0% *vs* 27.2%, respectively, *P* = 0.697) compared to clinical stage III.Overall rates of TME without sphincter preservation were similar between clinical stage II and III, 30.0% *vs* 30.3%, respectively, and similar if preoperative treatment was neoadjuvant chemoradiation (31.3%, *n* = 9762 TME without sphincter preservation out of *n* = 31160 that received neoadjuvant chemoradiation) or TNT (30.2%, *n* = 1302 TME without sphincter preservation out of *n* = 4302 that received TNT).

***Surgical approach and quality of resection***

Rates of open resection in the cohort were approximately 50%, but over the period of the study decreased from 69.4% in 2010 to 36.8% in 2016. There were concomitant rises in laparoscopic resection from 24.9% to 32.5% and robotic resection 5.6% to 30.7% (*P* < 0.001) (Figure 2). Open approach was used for 60% of TME without sphincter preservation compared to 47% of TME with sphincter preservation (*P* < 0.001).

The distribution of surgical approach is described in Table 2. Conversion to an open operation was lower with robotic approach (6.9%) compared to laparoscopy (14.5%). This was maintained regardless of whether sphincter sparing procedure was performed (conversion rate 15% laparoscopic, 6.9% robotic) or not (conversion rate 16.4% laparoscopic, 7.1% robotic), or whether TNT (conversion rate 15.6% laparoscopic, 6.5% robotic) was delivered.

R0 resection was obtained 94.8% of patients who underwent TME with sphincter preservation, and 90.3% of patients who underwent TME without sphincter preservation (*P* < 0.001). Twelve or more lymph nodes were examined more frequently in TME with sphincter preservation (71.6%) than without sphincter preservation (68.4%). Rates of R0 resection and 12+ lymph nodes harvested were both lower with open, compared to minimally invasive, approaches.

***Overall survival***

Table 3 summarizes factors impacting overall survival in this cohort. After adjustment, TME without sphincter preservation was associated with worse survival HR 1.30 (95%CI 1.20-1.40) compared to sphincter preservation. Interestingly, this cohort showed improved survival for minimally invasive approaches compared to open surgery (laparoscopy HR 0.85, 95%CI 0.78-0.93, and robotic HR 0.82, 95%CI 0.73-0.92). This improved survival in cases approached minimally invasively was sustained after stratification into TME with and without sphincter preservation (Figure 3).

**DISCUSSION**

This contemporary, nationwide cohort study identified an expected shift towards a minimally-invasive surgical approach for stage II/III rectal cancer with high quality surgical outcomes. Most of the patients are getting neoadjuvant radiation, but only a small fraction receives TNT. Neoadjuvant treatment at the population level does not seem to affect sphincter-sparing rates. Interestingly, this cohort also showed improved survival in cases approached minimally invasively - a finding that is at odds with prior, high-quality randomized control trials, but may reflect important differences between the randomized control trial population and surgeon and patient selection that occur in broader practice.

Contemporary treatment for rectal cancer is multidisciplinary. The most common neoadjuvant regimen utilizes chemoradiotherapy, which has been shown to lower the recurrence rate and is associated with less toxicity than post-operative radiation, with no difference in overall survival[14]. Additionally, neoadjuvant therapy may promote tumor shrinkage and affect sphincter-sparing rates. Still, despite recommendations in national guidelines describing neoadjuvant treatment for locally advanced rectal cancer or nodal disease[15,16], variation in radiation delivery is seen[17,18]. Midura *et al*[19] identified that factors such as hospital volume and facility type affected delivery of neoadjuvant therapy, including decreased use of neoadjuvant therapy for higher stage rectal cancer at lower-volume, community cancer centers. Furthermore, total neoadjuvant therapy has been increasingly promoted, in which studies have reported local disease control and decreased recurrence rates[20]. A majority of patients in our cohort underwent some type of neoadjuvant treatment, and sphincter-sparing rates were similar in patients with stage II or stage III disease. A prior meta-analysis supports the approximate rate of permanent colostomy to be approximately 30%[21]. It is important to note that certain clinical features, such as tumor distance from the anal verge or patients’ prior continence status, which might influence the decision for a non-sphincter sparing operation, are not available in this dataset. Most decisions about sphincter preservation happen before surgery, and rates of low tumors and incontinence rates are not expected to have meaningfully changed during this time period.

The equivalence of minimally-invasive and open approaches for rectal cancer surgery continues to be debated. Laparoscopy and robotic-assisted colorectal surgery have enabled decreased length of hospital stay, better analgesia, and improved visibility and ergonomics, specifically in the pelvis[22-24]. However, adoption of MIS for rectal cancer has been controversial, as both the Z6051 and ALaCaRT trials were unable to establish non-inferiority of pathological outcomes for minimally invasive vs open resection in patients with rectal cancer[25,26]. Follow-up of these trials found no significant difference in survival between approaches, with Z6051 showing 2-year disease free survival (DFS) of 79.5% in the laparoscopic group and 83.5% in the open group and ALaCaRT showing 2-year DFS of 94% in the laparoscopic group and 93% in the open group[27,28]. Finally, the ROLARR trial found no significant difference in conversion to open laparotomy between conventional laparoscopy vs robotic-assisted surgery, and concluded no short term benefit of robotic surgery over laparoscopy[29]. Our findings of improved survival with minimally invasive approaches, even after adjustment for pathological stage, neoadjuvant treatment, and patient/center features, are at odds with these prior, high-quality studies. However, the NCDB has a wider, national representation, and the findings herein may reflect patient- and approach- selection in broader practice, including training, resources, and institutional factors that impact approach outside of randomized trial patients. For example, it is unclear if the improved resection margins and lymph node harvest in the laparoscopic and robotic subgroups are due to the approaches themselves or the cases that lent themselves to be approached minimally invasively (or the surgeons choosing a minimally-invasive approach in these cases). Additionally, our findings are limited by the absence of information regarding local recurrence rate. However, it is notable that this effect of surgical approach on survival in this national cohort was maintained even after adjustment for multiple confounders or when stratifying the analysis by the subgroups with and without sphincter preservation.

Local excision operations in the setting of stage II/III are controversial and deserve special mention in this cohort. Patients with stage II/III who underwent transanal local excision make up a minority of operations and are not the standard treatment because of the inability to evaluate mesorectal lymph nodes. Still, several studies have shown the feasibility of this approach in the setting of neoadjuvant treatment[30-33]. In select patients showing tumor response to short course radiotherapy or chemotherapy, high rates of organ preservation can be achieved. Therefore, patients and their surgeons may opt for this approach if facing a decision about permanent colostomy or if they are poor surgical candidates for the standard TME. Further randomized studies to better assess the feasibility of this approach, and long term follow up for meaningful oncologic outcomes are underway[34].

This study is further limited by the inability to address the magnitude of treatment response and the impact of treatment response on decisions for sphincter preservation and surgical approach. For instance, we were unable to assess clinical complete responders, which occurs as frequently as 20%-30%[20], and would not be included unless they underwent resection and pathology confirmed no residual tumor. Patients may avoid resection if they have a complete clinical response but would need an APR, so there is bias in this study such that APR surgery only occurred in those patients that likely did not have good response and still needed resection. This presumably also impacts overall survival estimates. Finally, there is a lack of data available regarding local staging studies that could lead to misclassification of clinical stage. For instance, it has been reported that magnetic resonance imaging, which has become the standard of care, can over-stage rectal cancer as high as 30%[35–37]. Misclassification of stage could result in undertreatment or overtreatment, and that cannot be determined using this dataset. Despite these limitations, this study provides important information regarding treatment delivery patterns.

**CONCLUSION**

At a national level, minimally invasive surgery has become the predominant approach for rectal cancer. Sphincter preservation rates, when patients undergo surgical resection, do not vary with delivery of neoadjuvant treatment. In this broad national cohort, both open surgery and non-sphincter sparing operations were associated with worse overall survival for patients with stage II/III rectal adenocarcinoma.

**ARTICLE HIGHLIGHTS**

***Research background***

It is not well described whether the contemporary, multi-disciplinary approaches to stage II/III rectal cancer are resulting in meaningful changes in sphincter preservation, surgical quality, or overall survival.

***Research motivation***

While we push to individualize treatment decisions, it is important to recognize whether contemporary patterns to increase minimally-invasive surgery (MIS) and neoadjuvant treatment offer meaningful change the expected outcome of locally advanced rectal cancer.

***Research objectives***

Describe broad uptake in sphincter preservation, minimally-invasive approaches to rectal cancer, and the associated surgical outcomes of resection margins, lymph node harvest, and overall survival.

***Research methods***

Retrospective 'real-world' cohort of National Cancer Database (NCDB) sites, limited to stage II/III surgically treated rectal cancer.

***Research results***

Neither stage nor neoadjuvant treatment made a meaningful impact on rates of permanent colostomy, which was about 30% across all subgroups. From 2010 to 2016, there was a broad shift to MIS (laparoscopic and robotic) approaches to rectal cancer. These MIS approaches were associated with more frequent negative margins, better lymph node harvest, and improved overall survival after adjustment.

***Research conclusions***

There has been a shift to MIS approaches to locally advanced rectal cancer. Sphincter preservation rates remain similar in contemporary years, despite increasing neoadjuvant therapy. In recent years, more cases at NCDB sites are done MIS, which associate with better surgical quality and improved overall survival in this study.

***Research perspectives***

The findings of improved surgical quality and overall survival in this cohort are in contrast to randomized trial data that preceded this study. This may highlight the difference between randomized patients are 'real-world' practices or call into question the need for more contemporary, and pragmatic, trials for locally advanced rectal cancer surgery.

**REFERENCES**

1 **Kapiteijn E**, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. *N Engl J Med* 2001; **345**: 638-646 [PMID: 11547717 DOI: 10.1056/NEJMoa010580]

2 **van Gijn W**, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Påhlman L, Glimelius B, van de Velde CJ; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. *Lancet Oncol* 2011; **12**: 575-582 [PMID: 21596621 DOI: 10.1016/S1470-2045(11)70097-3]

3 **Gastrointestinal Tumor Study Group**. Prolongation of the disease-free interval in surgically treated rectal carcinoma. *N Engl J Med* 1985; **312**: 1465-1472 [PMID: 2859523 DOI: 10.1056/NEJM198506063122301]

4 **Folkesson J**, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. *J Clin Oncol* 2005; **23**: 5644-5650 [PMID: 16110023 DOI: 10.1200/JCO.2005.08.144]

5 **Schou JV**, Larsen FO, Rasch L, Linnemann D, Langhoff J, Høgdall E, Nielsen DL, Vistisen K, Fromm A, Jensen BV. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. *Ann Oncol* 2012; **23**: 2627-2633 [PMID: 22473488 DOI: 10.1093/annonc/mds056]

6 **Chau I**, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. *J Clin Oncol* 2006; **24**: 668-674 [PMID: 16446339 DOI: 10.1200/JCO.2005.04.4875]

7 **Fernandez-Martos C**, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, Safont MJ, Salud A, Vera R, Massuti B, Escudero P, Alonso V, Bosch C, Martin M, Minsky BD. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†. *Ann Oncol* 2015; **26**: 1722-1728 [PMID: 25957330 DOI: 10.1093/annonc/mdv223]

8 **Cercek A**, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, Guillem JG, Paty PB, Yaeger R, Stadler ZK, Seier K, Gonen M, Segal NH, Reidy DL, Varghese A, Shia J, Vakiani E, Wu AJ, Crane CH, Gollub MJ, Garcia-Aguilar J, Saltz LB, Weiser MR. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. *JAMA Oncol* 2018; **4**: e180071 [PMID: 29566109 DOI: 10.1001/jamaoncol.2018.0071]

9 **Fukuokaya W**, Kimura T, Urabe F, Kimura S, Tashiro K, Tsuzuki S, Koike Y, Sasaki H, Miki K, Egawa S. Reply to Cengiz Beyan and Esin Beyan. Mean platelet volume may not be a significant prognostic factor in patients with metastatic castration-resistant prostate cancer. Int J Clin Oncol 97(2), 3-4, 2020. *Int J Clin Oncol* 2020; **25**: 2177-2178 [PMID: 33104908 DOI: 10.1007/s10147-020-01815-6]

10 **Conroy T**, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Lamfichekh N, Juzyna B, Jouffroy-Zeller C, Rullier E, Marchal F, Gourgou S, Castan F, Borg C; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* 2021; **22**: 702-715 [PMID: 33862000 DOI: 10.1016/S1470-2045(21)00079-6]

11 **Bahadoer RR**, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2021; **22**: 29-42 [PMID: 33301740 DOI: 10.1016/S1470-2045(20)30555-6]

12 **Dietz DW**, Consortium for Optimizing Surgical Treatment of Rectal Cancer (OSTRiCh). Multidisciplinary management of rectal cancer: the OSTRICH. *J Gastrointest Surg* 2013; **17**: 1863-1868 [PMID: 23884558 DOI: 10.1007/s11605-013-2276-4]

13 **Novotny PJ,** Tan AD, Foster NR, Sloan JA. SAS® Tools for Cost Effective and High Quality Clinical Trial Reporting. SAS Global Forum 2012

14 **Sauer R**, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rödel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. *J Clin Oncol* 2012; **30**: 1926-1933 [PMID: 22529255 DOI: 10.1200/JCO.2011.40.1836]

15 **You YN**, Hardiman KM, Bafford A, Poylin V, Francone TD, Davis K, Paquette IM, Steele SR, Feingold DL; On Behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer. *Dis Colon Rectum* 2020; **63**: 1191-1222 [PMID: 33216491 DOI: 10.1097/DCR.0000000000001762]

16 **National Comprehensive Cancer Network**. Rectal Cancer (Version 1.2021). (cited 10 May, 2021). Available from: https://www.nccn.org/professionals/physician\_gls/pdf/rectal.pdf

17 **Fitzgerald TL**, Zervos E, Wong JH. Patterns of Pelvic Radiotherapy in Patients with Stage II/III Rectal Cancer. *J Cancer Epidemiol* 2013; **2013**: 408460 [PMID: 24223589 DOI: 10.1155/2013/408460]

18 **Morris EJA**, Finan PJ, Spencer K, Geh I, Crellin A, Quirke P, Thomas JD, Lawton S, Adams R, Sebag-Montefiore D. Wide Variation in the Use of Radiotherapy in the Management of Surgically Treated Rectal Cancer Across the English National Health Service. *Clin Oncol (R Coll Radiol)* 2016; **28**: 522-531 [PMID: 26936609 DOI: 10.1016/j.clon.2016.02.002]

19 **Midura EF**, Jung AD, Daly MC, Hanseman DJ, Davis BR, Shah SA, Paquette IM. Cancer Center Volume and Type Impact Stage-Specific Utilization of Neoadjuvant Therapy in Rectal Cancer. *Dig Dis Sci* 2017; **62**: 1906-1912 [PMID: 28501970 DOI: 10.1007/s10620-017-4610-2]

20 **Kasi A**, Abbasi S, Handa S, Al-Rajabi R, Saeed A, Baranda J, Sun W. Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2020; **3**: e2030097 [PMID: 33326026 DOI: 10.1001/jamanetworkopen.2020.30097]

21 **Gerard JP**, Rostom Y, Gal J, Benchimol D, Ortholan C, Aschele C, Levi JM. Can we increase the chance of sphincter saving surgery in rectal cancer with neoadjuvant treatments: lessons from a systematic review of recent randomized trials. *Crit Rev Oncol Hematol* 2012; **81**: 21-28 [PMID: 21377377 DOI: 10.1016/j.critrevonc.2011.02.001]

22 **Schootman M**, Hendren S, Ratnapradipa K, Stringer L, Davidson NO. Adoption of Robotic Technology for Treating Colorectal Cancer. *Dis Colon Rectum* 2016; **59**: 1011-1018 [PMID: 27749475 DOI: 10.1097/DCR.0000000000000688]

23 **Damle A**, Damle RN, Flahive JM, Schlussel AT, Davids JS, Sturrock PR, Maykel JA, Alavi K. Diffusion of technology: Trends in robotic-assisted colorectal surgery. *Am J Surg* 2017; **214**: 820-824 [PMID: 28347491 DOI: 10.1016/j.amjsurg.2017.03.020]

24 **Lee GI**, Lee MR, Green I, Allaf M, Marohn MR. Surgeons' physical discomfort and symptoms during robotic surgery: a comprehensive ergonomic survey study. *Surg Endosc* 2017; **31**: 1697-1706 [PMID: 27515836 DOI: 10.1007/s00464-016-5160-y]

25 **Fleshman J**, Branda M, Sargent DJ, Boller AM, George V, Abbas M, Peters WR Jr, Maun D, Chang G, Herline A, Fichera A, Mutch M, Wexner S, Whiteford M, Marks J, Birnbaum E, Margolin D, Larson D, Marcello P, Posner M, Read T, Monson J, Wren SM, Pisters PW, Nelson H. Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. *JAMA* 2015; **314**: 1346-1355 [PMID: 26441179 DOI: 10.1001/jama.2015.10529]

26 **Stevenson AR**, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebski VJ, Davies L, Wilson K, Hague W, Simes J; ALaCaRT Investigators. Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial. *JAMA* 2015; **314**: 1356-1363 [PMID: 26441180 DOI: 10.1001/jama.2015.12009]

27 **Fleshman J**, Branda ME, Sargent DJ, Boller AM, George VV, Abbas MA, Peters WR Jr, Maun DC, Chang GJ, Herline A, Fichera A, Mutch MG, Wexner SD, Whiteford MH, Marks J, Birnbaum E, Margolin DA, Larson DW, Marcello PW, Posner MC, Read TE, Monson JRT, Wren SM, Pisters PWT, Nelson H. Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial. *Ann Surg* 2019; **269**: 589-595 [PMID: 30080730 DOI: 10.1097/SLA.0000000000003002]

28 **Stevenson ARL**, Solomon MJ, Brown CSB, Lumley JW, Hewett P, Clouston AD, Gebski VJ, Wilson K, Hague W, Simes J; Australasian Gastro-Intestinal Trials Group (AGITG) ALaCaRT investigators. Disease-free Survival and Local Recurrence After Laparoscopic-assisted Resection or Open Resection for Rectal Cancer: The Australasian Laparoscopic Cancer of the Rectum Randomized Clinical Trial. *Ann Surg* 2019; **269**: 596-602 [PMID: 30247332 DOI: 10.1097/SLA.0000000000003021]

29 **Jayne D**, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, Quirke P, West N, Rautio T, Thomassen N, Tilney H, Gudgeon M, Bianchi PP, Edlin R, Hulme C, Brown J. Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial. *JAMA* 2017; **318**: 1569-1580 [PMID: 29067426 DOI: 10.1001/jama.2017.7219]

30 **Borschitz T**, Wachtlin D, Möhler M, Schmidberger H, Junginger T. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. *Ann Surg Oncol* 2008; **15**: 712-720 [PMID: 18163173 DOI: 10.1245/s10434-007-9732-x]

31 **Verseveld M**, de Graaf EJ, Verhoef C, van Meerten E, Punt CJ, de Hingh IH, Nagtegaal ID, Nuyttens JJ, Marijnen CA, de Wilt JH; CARTS Study Group. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). *Br J Surg* 2015; **102**: 853-860 [PMID: 25847025 DOI: 10.1002/bjs.9809]

32 **Bach SP**, Gilbert A, Brock K, Korsgen S, Geh I, Hill J, Gill T, Hainsworth P, Tutton MG, Khan J, Robinson J, Steward M, Cunningham C, Levy B, Beveridge A, Handley K, Kaur M, Marchevsky N, Magill L, Russell A, Quirke P, West NP, Sebag-Montefiore D; TREC collaborators. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. *Lancet Gastroenterol Hepatol* 2021; **6**: 92-105 [PMID: 33308452 DOI: 10.1016/S2468-1253(20)30333-2]

33 **Kennecke HF**, Brown CJ, Loree JM, Moloo H, Jonker DJ, Raval M, et al CCTG CO.28 primary endpoint analysis: Neoadjuvant chemotherapy, excision and observation for early rectal cancer, the NEO trial. *J Clin Oncol* 2021; **39**: 3508 [DOI: 10.1200/jco.2021.39.15\_suppl.3508]

34 **Rombouts AJM**, Al-Najami I, Abbott NL, Appelt A, Baatrup G, Bach S, Bhangu A, Garm Spindler KL, Gray R, Handley K, Kaur M, Kerkhof E, Kronborg CJ, Magill L, Marijnen CAM, Nagtegaal ID, Nyvang L, Peters FP, Pfeiffer P, Punt C, Quirke P, Sebag-Montefiore D, Teo M, West N, de Wilt JHW; for STAR-TREC Collaborative Group. Can we *S*ave the rectum by watchful waiting or *T*rans*A*nal microsurgery following (chemo) *R*adiotherapy versus *T*otal mesorectal excision for early *RE*ctal *C*ancer (STAR-TREC study)?: protocol for a multicentre, randomised feasibility study. *BMJ Open* 2017; **7**: e019474 [PMID: 29288190 DOI: 10.1136/bmjopen-2017-019474]

35 **Beets-Tan RG**. MRI in rectal cancer: the T stage and circumferential resection margin. *Colorectal Dis* 2003; **5**: 392-395 [PMID: 12925068 DOI: 10.1046/j.1463-1318.2003.00518.x]

36 **MERCURY Study Group**. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. *Radiology* 2007; **243**: 132-139 [PMID: 17329685 DOI: 10.1148/radiol.2431051825]

37 **Taylor FG**, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, Sebag-Montefiore DJ, Tekkis P, Brown G; MERCURY study group. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. *Ann Surg* 2011; **253**: 711-719 [PMID: 21475011 DOI: 10.1097/SLA.0b013e31820b8d52]

**Footnotes**

Institutional review board statement: The study was reviewed and approved for publication by our Institutional Reviewer.

Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.

Data sharing statement: No additional data are available.

**STROBE statement:** The authors have read the STROBE statement, and the manuscript was prepared and revised according to the STROBE statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** American Society of Colon and Rectal Surgeons; American College of Surgeons; Society of Surgeons of the Alimentary Tract; SWOG Cancer Research Network.

**Peer-review started:** December 29, 2021

**First decision:** March 13, 2022

**Article in press:** May 22, 2022

**Specialty type:** Surgery

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Chen SY, China; Han JG, China; Lee TG, South Korea **A-Editor:** Liu X, China **S-Editor:** Zhang H **L-Editor:** A **P-Editor:** Zhang H

**Figure Legends**

****

**Figure 1 CONSORT diagram of inclusion and exclusion criteria for cohort creation and survival analysis.**

****

**Figure 2 Distribution of surgical approach for stage II/III rectal cancer by year of diagnosis.**



**Figure 3 Kaplan-Meier curves of overall survival, stratified by surgical approach for total mesorectal excision** **with and without sphincter preservation.** A: With sphincter preservation; B: Without sphincter preservation. Shaded areas represent pointwise 95%CIs.

**Table 1** **Patient and facility demographics of patients with clinical stage II/III rectal cancer, stratified total mesorectal excision and sphincter preservation**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Local excision (*n* = 1442)** | **TME with sphincter preservation (*n* = 25737)** | **TME without sphincter preservation (*n* = 11748)** | **Total (*n* = 38927)** | ***P* value** |
| Age at diagnosis |  |  |  |  | < 0.0011 |
| mean ± SD | 66.2 ± 14.13 | 60.3 ± 12.47 | 61.6 ± 12.72 | 60.9 ± 12.67 |  |
| Sex |  |  |  |  | < 0.0012 |
| Male | 787 (54.6%) | 15810 (61.4%) | 7251 (61.7%) | 23848 (61.3%) |  |
| Charleson Comorbidity Score |  |  |  |  | < 0.0012 |
| 0 | 1057 (73.3%) | 19828 (77.0%) | 8828 (75.1%) | 29713 (76.3%) |  |
| 1 | 278 (19.3%) | 4486 (17.4%) | 2206 (18.8%) | 6970 (17.9%) |  |
| 2+ | 107 (7.4%) | 1423 (5.5%) | 714 (6.1%) | 2244 (5.8%) |  |
| Race3 |  |  |  |  | < 0.0012 |
| Black | 185 (12.8%) | 2006 (7.8%) | 1108 (9.4%) | 3299 (8.5%) |  |
| Other | 61 (4.2%) | 1501 (5.8%) | 562 (4.8%) | 2124 (5.5%) |  |
| White | 1183 (82.0%) | 22054 (85.7%) | 10012 (85.2%) | 33249 (85.4%) |  |
| Insurance status3 |  |  |  |  | < 0.0012 |
| Medicare/medicaid/other government | 852 (59.1%) | 11308 (43.9%) | 5825 (49.6%) | 17985 (46.2%) |  |
| Not insured | 38 (2.6%) | 1019 (4.0%) | 663 (5.6%) | 1720 (4.4%) |  |
| Private insurance/managed care | 518 (35.9%) | 13117 (51.0%) | 5066 (43.1%) | 18701 (48.0%) |  |
| Living location3 |  |  |  |  | < 0.0012 |
| Metropolitan | 1164 (83.2%) | 20618 (82.2%) | 9142 (79.4%) | 30924 (81.4%) |  |
| Rural | 30 (2.1%) | 548 (2.2%) | 295 (2.6%) | 873 (2.3%) |  |
| Urban | 205 (14.7%) | 3916 (15.6%) | 2083 (18.1%) | 6204 (16.3%) |  |
| Facility type3 |  |  |  |  | < 0.0012 |
| Academic/research program | 540 (37.4%) | 9852 (38.3%) | 4536 (38.6%) | 14928 (38.3%) |  |
| Community cancer program | 95 (6.6%) | 1453 (5.6%) | 711 (6.1%) | 2259 (5.8%) |  |
| Comprehensive community cancer program | 562 (39.0%) | 9593 (37.3%) | 4538 (38.6%) | 14693 (37.7%) |  |
| Integrated network cancer program | 193 (13.4%) | 3689 (14.3%) | 1451 (12.4%) | 5333 (13.7%) |  |
| Facility geographic region3 |  |  |  |  | < 0.0012 |
| Midwest | 343 (24.7%) | 6883 (28.0%) | 3528 (31.4%) | 10754 (28.9%) |  |
| Northeast | 313 (22.5%) | 5040 (20.5%) | 2027 (18.0%) | 7380 (19.8%) |  |
| South | 533 (38.3%) | 8522 (34.7%) | 3983 (35.4%) | 13038 (35.0%) |  |
| West | 201 (14.5%) | 4142 (16.8%) | 1698 (15.1%) | 6041 (16.2%) |  |

1Kruskal Wallis.

2Chi-Square.

3Race unknown for 255 patients; Insurance unknown for 521 patients; Living location unknown for 926 patients; Facility type and geographic region unknown for 1714 locations.

TME: Total mesorectal excision.

**Table 2 Tumor characteristics and surgical quality by surgical approach**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Open (*n* = 19830)** | **Laparoscopic (*n* = 12144)** | **Robotic (*n* = 6953)** | **Total (*n* = 38927)** | ***P* value** |
| Clinical stage |   |   |   |   | < 0.0011 |
| II | 9286 (46.8%) | 5477 (45.1%) | 2906 (41.8%) | 17669 (45.4%) |   |
| III | 10544 (53.2%) | 6667 (54.9%) | 4047 (58.2%) | 21258 (54.6%) |   |
| Pathological stage |   |   |   |   | < 0.0011 |
| 0 | 508 (3.2%) | 323 (3.4%) | 222 (3.9%) | 1053 (3.4%) |   |
| 1 | 3801 (23.8%) | 2736 (28.7%) | 1669 (29.6%) | 8206 (26.3%) |   |
| 2 | 5416 (33.9%) | 2941 (30.8%) | 1669 (29.6%) | 10026 (32.2%) |   |
| 3 | 6107 (38.2%) | 3480 (36.5%) | 2044 (36.3%) | 11631 (37.3%) |   |
| 4 | 152 (1.0%) | 57 (0.6%) | 29 (0.5%) | 238 (0.8%) |   |
| Chemotherapy sequence |   |   |   |   | < 0.0011 |
| No chemotherapy  | 2031 (10.2%) | 1397 (11.5%) | 459 (6.6%) | 3887 (10.0%) |   |
| Chemotherapy after surgery | 1864 (9.4%) | 1210 (10.0%) | 421 (6.1%) | 3495 (9.0%) |   |
| Chemotherapy before and after surgery | 5435 (27.4%) | 3691 (30.4%) | 2256 (32.4%) | 11382 (29.2%) |   |
| Chemotherapy before surgery | 10481 (52.9%) | 5840 (48.1%) | 3810 (54.8%) | 20131 (51.7%) |   |
| Radiation sequence |   |   |   |   | < 0.0011 |
| No radiation | 2449 (12.3%) | 1713 (14.1%) | 651 (9.4%) | 4813 (12.4%) |  |
| Radiation after surgery | 1470 (7.4%) | 911 (7.5%) | 315 (4.5%) | 2696 (6.9%) |   |
| Radiation before surgery | 15911 (80.2%) | 9515 (78.4%) | 5987 (86.1%) | 31418 (80.7%) |   |
| Total neoadjuvant therapy | 2194 (28.1%) | 1262 (25.1%) | 846 (28.0%) | 4302 (27.1%) | < 0.0011 |
| Surgery type |  |   |  |  | < 0.0011 |
| TME with sphincter preservation | 12118 (61.1%) | 8633 (71.1%) | 4986 (71.7%) | 25737 (66.1%) |   |
| TME without sphincter preservation | 7061 (35.6%) | 2760 (22.7%) | 1927 (27.7%) | 11748 (30.2%) |   |
| Conversion to open | 0 (0.0%) | 1760 (14.5%) | 480 (6.9%) | 2240 (11.7%) | < 0.0011 |
| Residual tumor |   |   |   |   | < 0.0011 |
| R0 | 18012 (91.9%) | 11174 (93.6%) | 6568 (95.1%) | 35754 (93.0%) |   |
| R1 | 806 (4.1%) | 413 (3.5%) | 193 (2.8%) | 1412 (3.7%) |   |
| R2 | 782 (4.0%) | 352 (2.9%) | 148 (2.1%) | 1282 (3.3%) |   |
| Number of lymph nodes examined (mean ± SD) | 14.7 ± 9.7 | 14.8 ± 9.8 | 15.7 ± 9.0 | 14.9 ± 9.6 | < 0.0011 |
| 12 or more lymph nodes examined | 13198 (67.1%) | 8148 (67.7%) | 5088 (73.6%) | 26434 (68.4%) | < 0.0011 |

1Chi-Square.

TME: Total mesorectal excision.

**Table 3 Unadjusted (univariate) and adjusted (multivariate) factors associated with overall survival**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Variable** | ***n*** | **Events** | **5-yr survival% (95%CI)** | **Cox univariate HR (95%CI)** | **Cox univariate score *P* value** | **Cox multivariate HR (95%CI)** | **Cox multivariate likelihood ratio *P* value (*n* = 15618)** |
| Age at diagnosis | 27114 | 5281 (19%) | 73.3 (72.6, 74.0) | 1.03 (1.03, 1.04) | < 0.0001 | 1.02 (1.02, 1.02) | < 0.0001 |
| Sex |  |   |   |   | < 0.0001 |   | < 0.0001 |
| Female | 10502 | 1869 (18%) | 75.5 (74.4, 76.6) |  |  |  |  |
| Male | 16612 | 3412 (21%) | 71.9 (70.9, 72.8) | 1.19 (1.13, 1.26) |  | 1.23 (1.14, 1.32) |  |
| Charleson comorbidity score |  |   |   |   | < 0.0001 |   | < 0.0001 |
| 0 | 20949 | 3656 (17%) | 75.7 (74.9, 76.5) |  |  |  |  |
| 1 | 4792 | 1202 (25%) | 67.4 (65.6, 69.1) | 1.43 (1.34, 1.53) |  | 1.25 (1.14, 1.36) |  |
| 2+ | 1373 | 423 (31%) | 58.5 (55.0, 62.0) | 2.00 (1.81, 2.22) |  | 1.59 (1.38, 1.82) |  |
| Race  |  |   |   |   | < 0.0001 |   | 0.3372 |
| Black | 2307 | 508 (22%) | 69.7 (67.1, 72.2) | 1.18 (1.08, 1.29) |  | 1.04 (0.92, 1.19) |  |
| Other | 1542 | 246 (16%) | 76.6 (73.6, 79.5) | 0.85 (0.74, 0.96) |  | 1.01 (0.85, 1.20) |  |
| White | 23091 | 4498 (19%) | 73.4 (72.7, 74.2) |  |  |  |  |
| Insurance status |  |   |   |   | < 0.0001 |   | < 0.0001 |
| Insurance status unknown | 382 | 64 (17%) | 71.8 (64.8, 78.8) | 1.46 (1.14, 1.88) |  | 0.93 (0.62, 1.39) |  |
| Medicare/medicaid/other government | 11607 | 3039 (26%) | 64.8 (63.6, 66.0) | 2.12 (2.01, 2.25) |  | 1.33 (1.22, 1.46) |  |
| Not insured | 1357 | 294 (22%) | 71.1 (67.9, 74.2) | 1.61 (1.42, 1.82) |  | 1.14 (0.97, 1.33) |  |
| Private insurance/managed care | 13768 | 1884 (14%) | 80.8 (79.9, 81.7) |  |  |  |  |
| Living location |  |   |   |   | 0.0407 |   | 0.3867 |
| Metropolitan | 21521 | 4134 (19%) | 73.7 (72.9, 74.5) |  |  |  |  |
| Rural | 611 | 117 (19%) | 72.9 (68.2, 77.6) | 1.01 (0.84, 1.22) |  | 0.85 (0.67, 1.08) |  |
| Urban | 4344 | 900 (21%) | 71.7 (69.9, 73.5) | 1.10 (1.02, 1.18) |  | 0.98 (0.89, 1.08) |  |
| Facility type |  |   |   |   | < 0.0001 |   | 0.5531 |
| Academic/research program | 10235 | 1850 (18%) | 75.4 (74.2, 76.5) |  |  |  |  |
| Community cancer program | 1624 | 384 (24%) | 67.4 (64.4, 70.5) | 1.37 (1.22, 1.53) |  | 1.00 (0.86, 1.17) |  |
| Comprehensive community cancer program | 10158 | 2097 (21%) | 71.6 (70.4, 72.8) | 1.17 (1.10, 1.25) |  | 1.06 (0.98, 1.15) |  |
| Integrated network cancer program | 3719 | 761 (20%) | 72.2 (70.2, 74.1) | 1.17 (1.07, 1.27) |  | 1.04 (0.93, 1.16) |  |
| Facility geographic region |  |   |   |   | 0.0008 |   | 0.0971 |
| Midwest | 7378 | 1455 (20%) | 73.6 (72.2, 74.9) | 0.91 (0.85, 0.97) |  | 0.926 (0.846, 1.014) |  |
| Northeast | 5058 | 967 (19%) | 74.1 (72.4, 75.7) | 0.87 (0.80, 0.94) |  | 0.912 (0.820, 1.014) |  |
| South | 9090 | 1885 (21%) | 71.2 (69.9, 72.4) |  |  |  |  |
| West | 4210 | 785 (19%) | 74.0 (72.2, 75.8) | 0.89 (0.82, 0.97) |  | 0.878 (0.783, 0.986) |  |
| Pathological stage |  |   |   |   | < 0.0001 |   | < 0.0001 |
| 0 | 782 | 66 (8%) | 89.2 (86.4, 92.1) |  |  |  |  |
| 1 | 5631 | 604 (11%) | 84.8 (83.5, 86.1) | 1.277 (0.990, 1.646) |  | 1.11 (0.84, 1.46) |  |
| 2 | 6861 | 1399 (20%) | 72.1 (70.6, 73.5) | 2.48 (1.94, 3.17) |  | 1.97 (1.50, 2.57) |  |
| 3 | 8247 | 2338 (28%) | 61.6 (60.2, 63.1) | 3.74 (2.93, 4.77) |  | 3.32 (2.55, 4.33) |  |
| 4 | 136 | 82 (60%) | 25.1 (15.6, 34.6) | 10.93 (7.90, 15.11) |  | 8.70 (5.97, 12.67) |  |
| Chemotherapy (multi or single agent) |  |   |   |   | < 0.0001 |   | 0.001 |
| Multiagent chemotherapy | 10043 | 1616 (16%) | 77.9 (76.8, 79.0) |  |  |  |  |
| Single-agent chemotherapy | 12445 | 2467 (20%) | 72.6 (71.5, 73.6) | 1.31 (1.23, 1.39) |  | 1.14 (1.06, 1.24) |  |
| Chemotherapy sequence |  |   |   |   | < 0.0001 |   | < 0.0001 |
| Chemotherapy after surgery | 2387 | 543 (23%) | 71.7 (69.4, 74.0) | 1.12 (1.02, 1.23) |  | 0.89 (0.75, 1.06) |  |
| Chemotherapy before surgery | 14351 | 2849 (20%) | 72.6 (71.6, 73.6) |  |  |  |  |
| Chemotherapy before and after surgery | 8128 | 1134 (14%) | 79.7 (78.5, 80.9) | 0.67 (0.63, 0.72) |  | 0.73 (0.67, 0.79) |  |
| Radiation sequence |  |   |   |   | < 0.0001 |   | 0.3489 |
| Radiation after surgery | 1934 | 463 (24%) | 70.5 (68.0, 73.1) | 1.30 (1.18, 1.43) |  | 0.92 (0.77, 1.10) |  |
| Radiation before surgery | 22529 | 4054 (18%) | 75.0 (74.2, 75.7) |  |  |  |  |
| Surgery type |  |   |   |   | < 0.0001 |   | < 0.0001 |
| Local excision | 953 | 249 (26%) | 65.0 (61.0, 69.1) | 1.62 (1.42, 1.84) |  | 1.26 (0.94, 1.68) |  |
| TME with sphincter preservation | 18237 | 3107 (17%) | 76.4 (75.6, 77.2) |  |  |  |  |
| TME without sphincter preservation | 7924 | 1925 (24%) | 67.5 (66.1, 68.8) | 1.44 (1.36, 1.53) |  | 1.30 (1.20, 1.40) |  |
| Surgical approach |  |   |   |  | < 0.0001 |   | < 0.0001 |
| Laparoscopic | 8510 | 1400 (16%) | 76.8 (75.5, 78.0) | 0.77 (0.72, 0.82) |  | 0.85 (0.78, 0.93) |  |
| Open | 14207 | 3300 (23%) | 70.7 (69.8, 71.7) |  |  |  |  |
| Robotic | 4397 | 581 (13%) | 75.7 (73.5, 77.8) | 0.72 (0.66, 0.79) |  | 0.82 (0.73, 0.92) |  |
| Tumor grade |  |   |   |   | < 0.0001 |   | < 0.0001 |
| Other (ND/UNK/NA/high grade dysplasia) | 3918 | 594 (15%) | 77.3 (75.5, 79.2) | 0.87 (0.80, 0.95) |  | 0.99 (0.88, 1.11) |  |
| Poor/undifferentiated | 3023 | 1004 (33%) | 58.9 (56.7, 61.1) | 1.97 (1.84, 2.11) |  | 1.67 (1.52, 1.83) |  |
| Well/moderate differentiation | 20173 | 3683 (18%) | 74.8 (74.0, 75.6) |  |  |  |  |
| Residual tumor |  |   |   |   | < 0.0001 |   | < 0.0001 |
| R0 | 24991 | 4432 (18%) | 75.5 (74.8, 76.2) |  |  |  |  |
| R1 | 932 | 414 (44%) | 44.5 (40.4, 48.6) | 3.03 (2.74, 3.36) |  | 2.23 (1.96, 2.54) |  |
| R2 | 869 | 347 (40%) | 46.5 (42.2, 50.9) | 2.76 (2.47, 3.08) |  | 1.99 (1.71, 2.30) |  |
| 12 or more lymph nodes examined |  |   |   |   | < 0.0001 |   | < 0.0001 |
| No | 8705 | 1919 (22%) | 70.9 (69.6, 72.1) | 1.19 (1.12, 1.25) |  | 1.26 (1.17, 1.36) |  |
| Yes | 18176 | 3317 (18%) | 74.5 (73.6, 75.4) |  |  |  |  |

TME: Total mesorectal excision.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**